Denali completes $195M sale of Priority Review Voucher from Hunter syndrome drug approval

Denali Therapeutics closed the sale of its Priority Review Voucher for $195 million in gross proceeds on July 27, 2026. The company received the PRV when the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome, a rare genetic disorder, in March 2026. Under FDA programs designed to incentivize development of treatments for rare pediatric diseases, companies receive these valuable vouchers that can be sold to other pharmaceutical companies seeking to expedite regulatory review of their own drug applications.

The $195 million cash inflow materially strengthens Denali's balance sheet and provides capital for ongoing operations, research and development programs, or other corporate purposes. For a biotech company, monetizing a PRV represents an efficient way to convert a regulatory incentive into immediate funding without diluting shareholders. The transaction demonstrates both the value of Denali's rare disease development capabilities and its ability to generate non-dilutive capital from successful drug approvals.